• 1
    Folkman J. Angiogenesis. Annu Rev Med. 2006; 57: 118.
  • 2
    ten Hagen TL,Eggermont AM. Solid tumor therapy: manipulation of the vasculature with TNF. Technol Cancer Res Treat. 2003; 2: 195203.
  • 3
    Scarpati EM,Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem. 1989; 264: 2070520713.
  • 4
    Brett J,Gerlach H,Nawroth P,Steinberg S,Godman G,Stern D. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med. 1989; 169: 19771991.
  • 5
    Friedl J,Puhlmann M,Bartlett DL, et al. Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood. 2002; 100: 13341339.
  • 6
    Lienard D,Eggermont AM,Kroon BB,Schraffordt Koops H,Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998; 14: 202209.
  • 7
    Eggermont AM,Schraffordt Koops H,Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996; 224: 756764; discussion 764–755.
  • 8
    Alexander HRJr,Bartlett DL,Libutti SK,Fraker DL,Moser T,Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998; 16: 14791489.
  • 9
    Hajitou A,Trepel M,Lilley CE, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell. 2006; 125: 385398.
  • 10
    Zacher AN3rd,Stock CA,Golden JW2nd,Smith GP. A new filamentous phage cloning vector: fd-tet. Gene. 1980; 9: 127140.
  • 11
    Yao VJ,Ozawa MG,Varner AS, et al. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res. 2006; 66: 26392649.
  • 12
    Larocca D,Witte A,Johnson W,Pierce GF,Baird A. Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum Gene Ther. 1998; 9: 23932399.
  • 13
    Hajitou A,Rangel R,Trepel M, et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat Protoc. 2007; 2: 523531.
  • 14
    Hwu P,Yannelli J,Kriegler M, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol. 1993; 150: 41044115.
  • 15
    Lederberg J. Smaller fleas. Ad infinitum: therapeutic bacteriophage redux. Proc Natl Acad Sci USA. 1996; 93: 31673168.
  • 16
    Larocca D,Burg MA,Jensen-Pergakes K,Ravey EP,Gonzalez AM,Baird A. Evolving phage vectors for cell targeted gene delivery. Curr Pharm Biotechnol. 2002; 3: 4557.
  • 17
    Hajitou A,Pasqualini R,Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med. 2006; 16: 8088.
  • 18
    Arap W,Pasqualini R,Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279: 377380.
  • 19
    Pasqualini R,Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380: 364366.
  • 20
    Pasqualini R,Koivunen E,Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997; 15: 542546.
  • 21
    Arap W,Kolonin MG,Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med. 2002; 8: 121127.
  • 22
    Cheresh DA,Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987; 262: 1770317711.
  • 23
    Lanza P,Felding-Habermann B,Ruggeri ZM,Zanetti M,Billetta R. Selective interaction of a conformationally constrained Arg-Gly-Asp (RGD) motif with the integrin receptor alphavbeta3 expressed on human tumor cells. Blood Cells Mol Dis. 1997; 23: 230241.
  • 24
    Larocca D,Kassner PD,Witte A,Ladner RC,Pierce GF,Baird A. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 1999; 13: 727734.
  • 25
    Poul MA,Marks JD. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999; 288: 203211.
  • 26
    Larocca D,Jensen-Pergakes K,Burg MA,Baird A. Receptor-targeted gene delivery using multivalent phagemid particles. Mol Ther. 2001; 3: 476484.
  • 27
    Nakamura T,Sato K,Hamada H. Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther. 2002; 13: 613626.
  • 28
    Balza E,Mortara L,Sassi F, et al. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res. 2006; 12: 25752582.
  • 29
    Crippa L,Gasparri A,Sacchi A,Ferrero E,Curnis F,Corti A. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha. Cancer Res. 2008; 68: 11541161.
  • 30
    Curnis F,Sacchi A,Borgna L,Magni F,Gasparri A,Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol. 2000; 18: 11851190.
  • 31
    Wang H,Chen K,Cai W, et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther. 2008; 7: 10441053.
  • 32
    Tandle A,Blazer DG3rd,Libutti SK. Antiangiogenic gene therapy of cancer: recent developments [serial online]. J Transl Med. 2004; 2: 22.
  • 33
    Brouckaert PG,Everaerdt B,Libert C,Takahashi N,Fiers W. Species specificity and involvement of other cytokines in endotoxic shock action of recombinant tumour necrosis factor in mice. Agents Actions. 1989; 26: 196198.
  • 34
    Fransen L,Ruysschaert MR,Van der Heyden J,Fiers W. Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines. Cell Immunol. 1986; 100: 260267.
  • 35
    Kramer SM,Aggarwal BB,Eessalu TE, et al. Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res. 1988; 48: 920925.
  • 36
    Daniel D,Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets. 2008; 8: 124131.
  • 37
    Lejeune FJ,Lienard D,Matter M,Ruegg C. Efficiency of recombinant human TNF in human cancer therapy [serial online]. Cancer Immun. 2006; 6: 6.
  • 38
    van Horssen R,Ten Hagen TL,Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006; 11: 397408.